metaEvidence - overview


			DCR
mML - L1 - all population metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - all population
versus ipilimumab alone
	nivolumab alone vs. ipilimumab alone	1	-
	nivolumab plus ipilimumab vs. ipilimumab alone	2	-
versus ipilimumab followed by nivolumab
	nivolumab followed by ipilimumab vs. ipilimumab followed by nivolumab	1	-
versus nivolumab alone
	nivolumab plus ipilimumab vs. nivolumab alone	1	-
	relatlimab plus nivolumab vs. nivolumab alone	1	-
versus Standard of Care (SoC)
	tremelimumab vs. Standard of Care (SoC)	1	-
mML - L1 - BRAF mutant metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF mutant
versus ipilimumab alone
	nivolumab plus ipilimumab vs. ipilimumab alone	1	-
versus placebo plus SoC
	atezolizumab plus SoC vs. placebo plus SoC	1	-
mML - L1 - BRAF wild metastatic/adv melanoma (mML) mML - 1st line (L1) mML - L1 - BRAF wild
versus dacarbazine
	nivolumab alone vs. dacarbazine	1	-
versus ipilimumab alone
	nivolumab plus ipilimumab vs. ipilimumab alone	1	-
versus pembrolizumab alone
	atezolizumab plus cometinib vs. pembrolizumab alone	1